SCHEMBL1726145

SCHEMBL1726145

O=C(NCC=Cc1cccc(S(=O)(=O)CC2(O)CCCCC2)c1)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 4/20 0.35
CYP3A4 P08684 2/20 0.31
CYP2C19 P33261 2/20 0.31
GAA P10253 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC3 O15379 2/20 0.30
HDAC4 P56524 2/20 0.30
HDAC1 Q13547 2/20 0.30
HDAC7 Q8WUI4 2/20 0.30
HDAC2 Q92769 2/20 0.30
HDAC10 Q969S8 2/20 0.30
HDAC11 Q96DB2 2/20 0.30
HDAC8 Q9BY41 2/20 0.30
HDAC6 Q9UBN7 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1726144 1.00 RORC (0.35) RORCCYP3A4CYP2C19GAACA12
SCHEMBL3388491 0.81 ALDH1A1 (0.39) RORCGAACYP2D6KMT2AHDAC6
SCHEMBL3388493 0.81 ALDH1A1 (0.39) RORCGAACYP2D6KMT2AHDAC6
SCHEMBL613406 0.80 CYP4F2 (0.38) CYP3A4CYP2C19CYP2D6CYP2C9HDAC3
SCHEMBL613405 0.80 CYP4F2 (0.38) CYP3A4CYP2C19CYP2D6CYP2C9HDAC3
SCHEMBL3131596 0.80 CYP1A2 (0.37) CYP3A4CYP2C19CYP2D6CYP2C9KMT2A
SCHEMBL3131602 0.80 CYP1A2 (0.37) CYP3A4CYP2C19CYP2D6CYP2C9KMT2A
SCHEMBL3390215 0.80 AOC2 (0.36) RORCKMT2AHDAC3HDAC4HDAC1
SCHEMBL3390221 0.80 AOC2 (0.36) RORCKMT2AHDAC3HDAC4HDAC1
SCHEMBL3383726 0.79 ALDH1A1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344451-A2 SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS Acucela, Inc. (US) 2011-07-20 EP disclosed
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-04-15 US disclosed
WO-2010028088-A2 SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, MPST, CLN6 RORC 987/4885CYP3A4 4354/4885CYP2C19 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.